Top

Strahlentherapie und Onkologie

Published in:

01-02-2014 | Case study

Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib

Two case reports

Authors: B. Schulze, MD, M. Meissner, M. Wolter, C. Rödel, C. Weiss

Published in: Strahlentherapie und Onkologie | Issue 2/2014

Abstract

Background

Besides radiotherapy (RT) and surgery, the introduction of BRAF inhibitors like vemurafenib has provided new opportunities for treatment of patients with metastasized malignant melanomas. RT and vemurafenib are being increasingly used concurrently, although little is known about the potential side effects of this combination. Vemurafenib is known to cause severe cutaneous skin reactions such as phototoxicity and evidence is accumulating that RT may further enhance these side effects.

Patients and methods

We report two cases of unusual skin reactions occurring during and after treatment with a combination of vemurafenib and whole-brain irradiation in patients with cerebral metastases arising from malignant melanomas.

Results

One case report describes excessive acute radiodermatitis which arose during whole-brain irradiation in combination with vemurafenib. The second describes a late skin reaction occurring approximately 30 days after completion of RT.

Conclusion

These two case reports show that combination of both treatment modalities is possible, but requires close monitoring of patients and good interdisciplinary collaboration.

Amer MH, Al-Sarraf M, Baker LH et al (1978) Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42:660–668PubMedCrossRef

Anker CJ, Ribas A, Grossmann AH et al (2013) Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol

Ascierto PA, Kirkwood JM, Grob JJ et al (2012) The role of BRAF V600 mutation in melanoma. J Transl Med 10:85PubMedCentralPubMedCrossRef

Boussemart L, Boivin C, Claveau J et al (n d) Vemurafenib and Radiosensitization. JAMA Dermatol 2013:1–3

Boussemart L, Routier E, Mateus C et al (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 24:1691–1697PubMedCrossRef

Brose MS, Volpe P, Feldman M et al (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997–7000PubMed

Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516PubMedCentralPubMedCrossRef

Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef

Dummer R, Rinderknecht J, Goldinger SM (2012) Ultraviolet a and photosensitivity during vemurafenib therapy. N Engl J Med 366:480–481PubMedCrossRef

10.

Dziggel L, Segedin B, Podvrsnik NH et al (2013) Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol 189:364–366PubMedCrossRef

11.

Fife KM, Colman MH, Stevens GN et al (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293–1300PubMedCrossRef

12.

Fokas E, Steinbach JP, Rodel C (2013) Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim Biophys Acta 1835:61–75PubMed

13.

Gani C, Muller AC, Eckert F et al (2012) Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors. Strahlenther Onkol 188:148–153PubMedCrossRef

14.

Narayana A, Mathew M, Tam M et al (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol

15.

Oberholzer PA, Kee D, Dziunycz P et al (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316–321PubMedCrossRef

16.

Ramakrishna N, Margolin KA (2013) Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am Soc Clin Oncol Educ Book 2013:399–403CrossRef

17.

Retsas S, Gershuny AR (1988) Central nervous system involvement in malignant melanoma. Cancer 61:1926–1934PubMedCrossRef

18.

Sampson JH, Carter JH Jr, Friedman AH et al (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11–20PubMedCrossRef

19.

Satzger I, Degen A, Asper H et al (2013) Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy. J Clin Oncol 31:e220–e222PubMedCrossRef

20.

Sinha R, Edmonds K, Newton-Bishop JA et al (2012) Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 167:987–994PubMedCrossRef

21.

Sloan AE, Nock CJ, Einstein DB (2009) Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 16:248–255PubMed

22.

Staudt M, Lasithiotakis K, Leiter U et al (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213–1218PubMedCentralPubMedCrossRef

23.

Su F, Viros A, Milagre C et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207–215PubMedCentralPubMedCrossRef

Title: Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib
Two case reports
Authors: B. Schulze, MD
M. Meissner
M. Wolter
C. Rödel
C. Weiss
Publication date: 01-02-2014
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 2/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0474-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib

Two case reports

Abstract

Background

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2014

Berechnungen der „equivalent uniform dose“ zur akzelerierten Teilbrustbestrahlung mit dem MammoSite-Applikator

Zusatz von Cetuximab zur primären Radiochemotherapie von Ösophaguskarzinomen verursacht schlechteres Gesamtüberleben

Patients who die during palliative radiotherapy

The QUIRO Study (assurance of quality and innovation in radiooncology): methodology, instruments and practices

Effects of chemotherapy on the parotid and submandibular glands in head and neck cancer patients treated with chemoradiotherapy

Radio-induced apoptosis of peripheral blood CD8 T lymphocytes is a novel prognostic factor for survival in cervical carcinoma patients